著者

Yuki Yoshimatsu Noriyuki Ebi Ryunosuke Ooi Takuto Sueyasu Saori Nishizawa Miyuki Munechika Kohei Yoshimine Yuki Ko Hiromi Ide Kosuke Tsuruno Kazunori Tobino

出版者

The Japanese Society of Internal Medicine

雑誌

Internal Medicine (ISSN:09182918)

巻号頁・発行日

pp.5463-20, (Released:2020-11-02)

参考文献数

18

被引用文献数

5

---

The efficacy of epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs) in lung squamous cell carcinoma is said to be low. Thus far, only four cases of osimertinib in lung squamous cell carcinoma have been published. We experienced a case of EGFR mutant lung squamous cell carcinoma in which fifth-line treatment with osimertinib was effective after T790M EGFR mutation turned positive. Osimertinib was resumed after sixth-line chemotherapy was ineffective, showing efficacy again. Osimertinib may be a promising treatment option for EGFR mutant lung squamous cell carcinoma. This is the first report to show its effect in a case of rechallenge after intervening chemotherapy. It may therefore be important to evaluate EGFR in never-smoker lung squamous cell carcinoma patients.